NAMS NewAmsterdam Pharma Co N.V.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1936258 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-26.4%
TTM net income YoY7.3%
TTM EPS YoY17.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-900.1%
Net margin-789.9%
FCF margin-581.6%
EBITDA margin-899.0%
Returns
ROE-30.2%
ROA-27.8%
ROIC (approx.)-92.8%
Asset turnover0.04x
Leverage & solvency
Liabilities / assets8.3%
Debt / equity0.00x
Current ratio11.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · USD | FY20232023-12-31 · USD | FY20222022-12-31 · EUR | FY20212021-12-31 · EUR |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $22.50M | $45.56M | $14.09M | 97.50M | — |
| R&D expense | $141.83M | $151.41M | $159.42M | 82.23M | 25.03M |
| SG&A expense | $106.35M | $70.45M | $37.63M | 22.23M | 4.80M |
| Operating income | -$225.68M | -$176.29M | -$182.97M | -67.56M | -29.84M |
| Interest expense | — | — | — | 271,000 | 216,000 |
| Pretax income | -$203.82M | -$241.60M | -$176.91M | -78.05M | -28.60M |
| Income tax | — | -$1,000 | $27,000 | — | — |
| Net income | -$203.82M | -$241.60M | -$176.94M | -78.05M | -28.60M |
| EBITDA | -$225.46M | -$176.18M | -$182.92M | -67.49M | -29.82M |
| EPS (basic) | -1.72 | -2.56 | -2.15 | -1.97 | -1.21 |
| EPS (diluted) | -1.72 | -2.56 | -2.15 | -1.97 | -1.21 |
| Weighted avg. shares (diluted) | 118.42M | 94.36M | 82.16M | 18.97M | 11.09M |
| Balance sheet | |||||
| Cash & equivalents | $490.00M | $771.74M | $340.45M | 438.52M | 53.09M |
| Short-term investments | $146.24M | $62.45M | — | — | — |
| Current assets | $675.70M | $863.41M | $346.79M | 448.13M | 58.87M |
| PP&E, net | $383,000 | $242,000 | $46,000 | 144,000 | 190,000 |
| Intangibles | — | — | — | 83.16M | — |
| Total assets | $769.28M | $864.62M | $347.10M | 531.58M | 59.78M |
| Current liabilities | $85.79M | $106.92M | $49.90M | 35.46M | 9.88M |
| Total liabilities | $85.85M | $107.12M | $58.70M | $48.43MUSD | 9.99M |
| Shareholders' equity | $683.43M | $757.50M | $288.39M | $430.07MUSD | -$113.82MUSD |
| Shares outstanding | 114.40M | 108.06M | 82.47M | 81.56M | 11.33M |
| Cash flow statement | |||||
| Operating cash flow | -$147.78M | -$158.56M | -$141.22M | 7.97M | -25.16M |
| Capital expenditure | $246,000 | $672,000 | $24,000 | 13,000 | 20,000 |
| Free cash flow | -$148.03M | -$159.24M | -$141.24M | 7.96M | -25.18M |
| Investing cash flow | -$174.92M | -$62.85M | -$24,000 | 715,000 | -20,000 |
| Financing cash flow | $29.52M | $659.51M | $8.91M | 375.18M | 68.99M |
| Depreciation & amortization | $220,000 | $113,000 | $49,000 | 72,000 | 14,000 |
| Stock-based compensation | $59.42M | $33.62M | $24.57M | 3.92M | 1.05M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.